HYPERION DEFI, INC. Share-based Payment Arrangement, Expense
HYPERION DEFI, INC. (HYPD) reported Share-based Payment Arrangement, Expense of $1.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-13
- HYPERION DEFI, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $1.63M, a 71.23% decline year-over-year.
- HYPERION DEFI, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.80M, a 545.32% increase year-over-year.
- HYPERION DEFI, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.77M, a 976.77% increase year-over-year.
- HYPERION DEFI, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was -$1.35M, a 397.36% decline year-over-year.
- HYPERION DEFI, INC. share-based payment arrangement, expense for fiscal 2025 was $6.37M, a 273.88% increase from fiscal 2024.
- HYPERION DEFI, INC. share-based payment arrangement, expense for fiscal 2024 was $1.70M, a 31.77% decline from fiscal 2023.
- HYPERION DEFI, INC. share-based payment arrangement, expense for fiscal 2023 was $2.50M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-13 | $3.44M 10-Q · filed 2026-08-13 | $5.20M derived: sum of 3 quarters · filed 2026-08-13 | $3.86M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-15 | $3.57M derived: sum of 2 quarters · filed 2026-05-15 | $2.22M derived: sum of 3 quarters · filed 2026-05-15 | $7.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $418.73K derived: sum of 2 quarters · filed 2026-03-30 | $6.09M derived: sum of 3 quarters · filed 2026-08-13 | $6.37M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$1.35M 10-Q · filed 2025-11-14 | $4.33M derived: sum of 2 quarters · filed 2026-08-13 | $4.61M 10-Q · filed 2025-11-14 | $4.77M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $5.67M 10-Q · filed 2026-08-13 | $5.95M 10-Q · filed 2026-08-13 | $6.12M derived: sum of 3 quarters · filed 2026-08-13 | $6.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $279.63K 10-Q · filed 2026-05-15 | $443.62K derived: sum of 2 quarters · filed 2026-05-15 | $896.61K derived: sum of 3 quarters · filed 2026-05-15 | $1.44M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $163.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $616.99K derived: sum of 2 quarters · filed 2026-03-30 | $1.16M derived: sum of 3 quarters · filed 2026-03-30 | $1.70M 10-K · filed 2026-03-30 |
| 2024-09-30 | $453.00K 10-Q · filed 2025-11-14 | $994.05K derived: sum of 2 quarters · filed 2025-11-14 | $1.54M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $541.06K 10-Q · filed 2025-08-13 | $1.09M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $546.23K 10-Q · filed 2025-05-19 | |||
| 2023-12-31 | $2.50M 10-K · filed 2025-04-15 | |||
| 2018-06-30 | $1.51K 10-Q · filed 2018-08-14 | $652.09K 10-Q · filed 2018-08-14 | ||
| 2017-06-30 | $3.09K 10-Q · filed 2018-08-14 | $6.39K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |